Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2676)	1/22/2010 1:18:45 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

MNTA was up 22.58% at its intraday H, but is pu only 9.91% at present.<g> Volume of > 2,089,000 is almost 4x its ADV bigcharts.marketwatch.com Novartis said today that it aims to launch generic Lovenox as soon as it gets FDA approval,<g> The stock traded today above its Sep double top and with some good news it shouldn't have much problems in testing the Aug H at the $20 level.That would be a 42% gain from present levels.<g> bigcharts.marketwatch.com Bernard

To: Jibacoa who wrote (2676)	5/14/2010 2:52:29 PM
From: Jibacoa	Respond to of 3722

CRDC was up 3.9% and is still on the green up 1.46% in spite of the general market's "correction", with the DOW still holding above 10,500 <g> The stock is bouncing up from the support at the $2 level on volume of 64Ks about 1/3 its ADV bigcharts.marketwatch.com On May 4 it reported results for the 3rdQ in which it was able to trim its loss in half in spite of lower revenues.<g> During the Q it initiated animal trials for the Cardica Microcutter ES8 and they said they believe that they are on track to launch it in early 2011. This said that this line of products will include flexible and rigid shaft offerings in multiple sizes for use in a wide variety of laparoscopic or thorascopic procedures,which will provides a technological improvement for surgeons with cutting-stapling devices that are smaller, easier to use, and more flexible than existing products. Regarding their cardiac surgery business,they said they maintained a revenue rate of approximately $1M. The stock isn't off from its longer term DT coming from the Sep2008 H at $11.13 and the Oct2007 at $15.15 As previously mentioned, the ACTAY is $6 and I think I will keep a target unchanged at $3.19 <g> bigcharts.marketwatch.com Bernard